[French ccAFU guidelines - Update 2018-2020: Retroperitoneal sarcoma].

Prog Urol

Comité de cancérologie de l'Association française d'urologie, groupe organes génitaux externes, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, AP-HP, 75015 Paris, France.

Published: November 2018

Objective: To update French urological guidelines on retroperitoneal sarcoma.

Methods: Comprehensive Medline search between 2016 and 2018 upon diagnosis, treatment and follow-up of retroperitoneal sarcoma. Level of evidence was evaluated.

Results: Chest, abdomen and pelvis CT is mandatory to evaluate any suspected retroperitoneal sarcoma. MRI sometimes helps surgical planning. Before histological confirmation through biopsy, the patient must be registered in the French sarcoma pathology reference network. The biopsy standard should be an extraperitoneal coaxial percutaneous sampling before any retroperitoneal mass therapeutic decision. Surgery is retroperitoneal sarcoma cornerstone. The main objective is grossly negative margins and can be technically challenging. Multimodal treatment risks and benefits must be discussed in multidisciplinary teams. The relapse rate is related to tumor grade and surgical margins.

Conclusion: Retroperitoneal sarcoma prognosis is poor and closely related to the quality of initial management. Centralization through dedicated sarcoma pathology network in a high-volume center is mandatory.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2019.01.010DOI Listing

Publication Analysis

Top Keywords

retroperitoneal sarcoma
16
sarcoma pathology
8
retroperitoneal
7
sarcoma
6
[french ccafu
4
ccafu guidelines
4
guidelines - update
4
- update 2018-2020
4
2018-2020 retroperitoneal
4
retroperitoneal sarcoma]
4

Similar Publications

Granulosa tumors are rare tumors arising from the cells of the sexual cord and stroma of the ovary. They account for 5% of ovarian cancers and 70% of stromal cancers of the sex cords. Retroperitoneal tumors (RPTs) are also rare and develop in the retroperitoneal and subperitoneal space.

View Article and Find Full Text PDF

Purpose: Optimal treatment of retroperitoneal sarcoma (RPS) remains undefined. Here, we report the feasibility of using high-dose boost radiation (3-4 Gy) to the central part of the tumor in patients with unresectable RPS.

Methods And Materials: Five patients with unresectable RPS were treated with radiation therapy using a central boost technique with intensity modulated radiation therapy.

View Article and Find Full Text PDF

Soft tissue sarcomas (STSs) are rare malignancies, with retroperitoneal soft tissue sarcoma (RPS) constituting 10%-15% of all STSs. RPS often presents late due to minimal early symptoms, typically requiring complete en-bloc resection for optimal survival outcomes. Achieving radical resection can be challenging due to the tumor's proximity to vital organs.

View Article and Find Full Text PDF

Introduction: Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities. The manifestation of neuroblastoma is variable depending on the location of the tumor and the presence or absence of paraneoplastic syndromes.

View Article and Find Full Text PDF

Primary bronchial leiomyosarcoma: a diagnostic challenge.

BMC Pulm Med

January 2025

Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, P.R. China.

Background: Pulmonary bronchial leiomyosarcoma is an extremely rare malignant tumour of the lung originating from the mesenchymal tissue. The retroperitoneal region is the most common site of leiomyosarcoma. It exhibits a high degree of malignancy and a poor prognosis, thereby highlighting the significance of early diagnosis of this disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!